MOLRECORD
PAPER SUMMARY TRIAL Metabolic and the GLP-1 class

Retatrutide: four Phase 3 readouts in 2026

Topline results from the sponsor; full papers are still to come for most of the trials.

Published 5 Oct 2026 Event 19 Mar – 23 Jul 2026 Sources 4 EVIDENCE · CONTROLLED TRIALS (TOPLINE)PHASE · 3REGULATORY · NOT APPROVED · SUBMISSION Q1 2027
TRIALS
4
LARGEST N
2,339
DURATION
40–104 wks
STATUS
Topline

What was done

Retatrutide is an investigational once-weekly agonist of the GIP, GLP-1 and glucagon receptors. TRANSCEND-T2D-1 (type 2 diabetes, 40 weeks) reported on 19 March 2026; TRIUMPH-1 (obesity, 2,339 participants, 80 weeks with a 104-week extension) on 21 May; TRIUMPH-2 (obesity with type 2 diabetes) and TRIUMPH-3 (obesity with cardiovascular disease) on 23 July. [1][2][3]

What was found

In TRANSCEND-T2D-1 the 12 mg dose lowered A1C by 1.7 to 2.0 points and reduced body weight by 16.8 % at 40 weeks. In TRIUMPH-1, mean weight reduction at 80 weeks was 19.0 % (4 mg), 25.9 % (9 mg) and 28.3 % (12 mg) against 2.2 % on placebo; participants escalated to the highest tolerated dose reached 30.3 % at 104 weeks. TRIUMPH-2 reported 20.8 % and TRIUMPH-3 22.6 % at 80 weeks on 12 mg. [1][2][3][4]

Limits

All four are sponsor press releases, not peer-reviewed papers. Adverse events were described as consistent with the incretin class, with gastrointestinal effects predominant; discontinuation by dose is not fully reported in the releases. The cardiovascular outcomes trial is ongoing. [2][4]

Funding

Eli Lilly and Company, the developer, sponsored all four trials and issued the results. A regulatory submission is planned for the first quarter of 2027. [3]

SOURCES

  1. Eli Lilly and Company. Retatrutide demonstrated significant reductions in A1C and weight in first Phase 3 trial for type 2 diabetes. 19 Mar 2026. Press release. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
  2. Eli Lilly and Company. Lilly's triple agonist retatrutide delivered powerful weight loss (TRIUMPH-1). 21 May 2026. Press release. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss
  3. Eli Lilly and Company. Retatrutide successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). 23 Jul 2026. Press release. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
  4. HCPLive. Retatrutide meets weight loss endpoints in Phase 3 obesity trial. 21 May 2026. News report. https://www.hcplive.com/view/retatrutide-weight-loss-endpoints-phase-3-obesity-trial

CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN